China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
Stiffer Fines For Violators
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
You may also be interested in...
In its most recent regulatory reforms, China is proposing to allow online sales of prescription drugs, a major step forward that could boost struggling retail pharmacies and further propel medicine e-commerce.
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.